1. Савченко В.Г., Паровичникова Е.Н. Острые лейкозы // Клиническая онкогематология: руководство для врачей. Под ред. Волковой М.А. 2-е изд., перераб. и доп. 2007. P. 409 - 502.

2. Паровичникова Е.Н. et al. Клинический протокол ОМЛ-01.10 по лечению острых миелоидных лейкозов взрослых // Программное лечение заболеваний крови, под ред. Савченко В.Г. М.: Практика, 2012. P. 153 - 207.

3. Shallis R.M. et al. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. // Blood Rev. 2019. Vol. 36. P. 70 - 87.

4. Arber D.A. et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia // Blood. American Society of Hematology, 2016. Vol. 127, N 20. P. 2391 - 2405.

5. Khoury J. D. et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms // Leukemia, 2022. Vol. 36. P. 1703 - 1719.

6. Grimwade D., Hills R.K. Independent prognostic factors for AML outcome. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2009. P. 385 - 395.

7. D hner H. et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel // Blood. 2017. Vol. 129, N 4. P. 424 - 447.

8. Pollyea D.A. et al. Acute Myeloid Leukemia, Version 3.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw 2023 May;21(5):503-513. doi: 10.6004/jnccn.2023.0025.

9. D hner H. et al. Diagnosis and management of AML in adults: recommendations from an international expert panel on behalf of the ELN. Blood (2022) 140 (12): 1345 - 1377. doi.org/10.1182/blood.2022016867

10. Kulsoom B. et al. Clinical presentation of acute myeloid leukaemia - A decade-long institutional follow-up. // J. Pak. Med. Assoc. 2017. Vol. 67, N 12. P. 1837 - 1842.

11. Oken M.M. et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group // Am. J. Clin. Oncol. 1982. Vol. 5, N 6. P. 649 - 655.

12. Roila F. et al. Intra and interobserver variability in cancer patients' performance status assessed according to Karnofsky and ECOG scales // Ann. Oncol. Oxford University Press (OUP), 1991. Vol. 2, N 6. P. 437 - 439.

13. Wass M. et al. Value of different comorbidity indices for predicting outcome in patients with acute myeloid leukemia // PLoS One. 2016. Vol. 11, N 10. P. e0164587.

14. Mohammadi M. et al. The impact of comorbid disease history on all-cause and cancer-specific mortality in myeloid leukemia and myeloma - a Swedish population-based study. // BMC Cancer. 2015. Vol. 15. P. 850.

15. Agis H. et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis. // Ann. Hematol. 2002. Vol. 81, N 2. P. 90 - 95.

16. Avni B. et al. Clinical implications of acute myeloid leukemia presenting as myeloid sarcoma. // Hematol. Oncol. 2012. Vol. 30, N 1. P. 34 - 40.

17. D hner H. et al. Diagnosis and management of acute myeloid leukemia in adults: Recommendations from an international expert panel, on behalf of the European LeukemiaNet // Blood. Blood, 2010. Vol. 115, N 3. P. 453 - 474.

18. Ku G.H. et al. Venous thromboembolism in patients with acute leukemia: Incidence, risk factors, and effect on survival // Blood. 2009. Vol. 113, N 17. P. 3911 - 3917.

19. Lahoti A. et al. Predictors and outcome of acute kidney injury in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome // Cancer. 2010. Vol. 116, N 17. P. 4063 - 4068.

20. Fang R.C., Aboulafia D.M. HIV infection and myelodysplastic syndrome/acute myeloid leukemia // HIV-Associated Hematological Malignancies. 2016. P. 133 - 144.

21. Freeman A.J. et al. Estimating progression to cirrhosis in chronic hepatitis C virus infection. // Hepatology. 2001. Vol. 34, N 4 Pt 1. P. 809 - 816.

22. Ribas A. et al. How important is hepatitis C virus (HCV)-infection in persons with acute leukemia? // Leuk. Res. 1997. Vol. 21, N 8. P. 785 - 788.

23. Rossi D. et al. Occult hepatitis B virus infection of peripheral blood mononuclear cells among patients with chronic lymphocytic leukemia // Leuk. Lymphoma. 2009. Vol. 50, N 4. P. 604 - 611.

24. Chen CY, Huang SY, Cheng A, et al. High Risk of Hepatitis B Reactivation among Patients with Acute Myeloid Leukemia. PLoS One. 2015;10(5):e0126037.

25. Lam M.T. et al. Herpes simplex infection in acute myelogenous leukemia and other hematologic malignancies: a prospective study. // Cancer. 1981. Vol. 48, N 10. P. 2168 - 2171.

26. Bernson E. et al. Cytomegalovirus serostatus affects autoreactive NK cells and outcomes of IL2-based immunotherapy in acute myeloid leukemia // Cancer Immunol. Res. American Association for Cancer Research Inc., 2018. Vol. 6, N 9. P. 1110 - 1119.

27. Guan H. et al. Correlations between Epstein-Barr virus and acute leukemia // J. Med. Virol. John Wiley and Sons Inc., 2017. Vol. 89, N 8. P. 1453 - 1460.

28. Elmaagacli A.H., Koldehoff M. Cytomegalovirus replication reduces the relapse incidence in patients with acute myeloid leukemia // Blood. American Society of Hematology, 2016. Vol. 128, N 3. P. 456 - 459.

29. Averbuch D. et al. Targeted therapy against multi-resistant bacteria in leukemic and hematopoietic stem cell transplant recipients: Guidelines of the 4th European conference on Infections in Leukemia (ECIL-4, 2011) // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, N 12. P. 1836 - 1847.

30. Averbuch D. et al. European guidelines for empirical antibacterial therapy for febrile neutropenic patients in the era of growing resistance: Summary of the 2011 4th European Conference on Infections in Leukemia // Haematologica. Ferrata Storti Foundation, 2013. Vol. 98, N 12. P. 1826 - 1835.

31. Leahy M.F., Mukhtar S.A. From blood transfusion to patient blood management: a new paradigm for patient care and cost assessment of blood transfusion practice. // Intern. Med. J. 2012. Vol. 42, N 3. P. 332 - 338.

32. Olsen R.J. et al. Acute leukemia immunohistochemistry: a systematic diagnostic approach. // Arch. Pathol. Lab. Med. 2008. Vol. 132, N 3. P. 462 - 475.

33. Bene M.C. et al. Proposals for the immunological classification of acute leukemias. European Group for the Immunological Characterization of Leukemias (EGIL). // Leukemia. 1995. Vol. 9, N 10. P. 1783 - 1786.

34. Ravandi F., Walter R.B., Freeman S.D. Evaluating measurable residual disease in acute myeloid leukemia. // Blood Adv. 2018. Vol. 2, N 11. P. 1356 - 1366.

35. Лобанова Т.И., Гальцева И.В., Паровичникова Е.Н. Исследование минимальной остаточной болезни у пациентов с острыми миелоидными лейкозами методом многоцветной проточной цитофлуориметрии (обзор литературы) // Онкогематология. 2018. Vol. 13, N 1. P. 83 - 102.

36. Лобанова Т.И. "Клиренс опухолевого клона у пациентов с разными молекулярно-генетическими вариантами острых миелоидных лейкозов": диссертация ... кандидата медицинских наук: 14.01.21. 2018. 166 p.

37. Del Principe M.I. et al. Involvement of central nervous system in adult patients with acute myeloid leukemia: Incidence and impact on outcome // Seminars in Hematology. W.B. Saunders, 2018. Vol. 55, N 4. P. 209 - 214.

38. Herrmann J. et al. Evaluation and management of patients with heart disease and cancer: Cardio-oncology // Mayo Clin. Proc. 2014. Vol. 89, N 9. P. 1287 - 1306.

39. Roberts A.S. et al. Extramedullary haematopoiesis: radiological imaging features // Clinical Radiology. 2016. Vol. 71, N 9. P. 807 - 814.

40. Fritz J. et al. Radiologic spectrum of extramedullary relapse of myelogenous leukemia in adults. // AJR. Am. J. Roentgenol. 2007. Vol. 189, N 1. P. 209 - 218.

41. Arrigan M. et al. Imaging findings in recurrent extramedullary leukaemias // Cancer Imaging. 2013. Vol. 13, N 1. P. 26 - 35.

42. Seegars M.B., Powell B.L., Howard D.S. Acute Myeloid Leukemia in Pregnancy // Blood. 2017. Vol. 130, N Suppl 1. P. 5035.

43. Woitek R. et al. Radiological staging in pregnant patients with cancer // ESMO Open. 2016. Vol. 1, N 1. P. e000017.

44. Bodey G.P., Kontoyiannis D., Keating M.J. Infections in Patients With Chronic Lymphocytic Leukemia // Chronic Lymphocytic Leukemia. Totowa, NJ: Humana Press, 2004. P. 343 - 359.

45. Клясова Г.А. et al. Возбудители сепсиса у иммунокомпрометированных больных: структура и проблемы антибиотикорезистентности (результаты многоцентрового исследования) // Гематология и трансфузиология. 2007. Vol. 52, N 1. P. 11 - 18.

46. Cornelissen J.J. et al. The European LeukemiaNet AML Working Party consensus statement on allogeneic HSCT for patients with AML in remission: An integrated-risk adapted approach // Nature Reviews Clinical Oncology. 2012. Vol. 9, N 10. P. 579 - 590.

47. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство / под ред. Е.Н. Паровичниковой, Г.М. Галстяна. М.: Практика, 2024. 512 с.

48. Bertoli S. et al. Time from diagnosis to intensive chemotherapy initiation does not adversely impact the outcome of patients with acute myeloid leukemia. // Blood. 2013. Vol. 121, N 14. P. 2618 - 2626.

49. Sekeres M.A. et al. Time from diagnosis to treatment initiation predicts survival in younger, but not older, acute myeloid leukemia patients // Blood. 2009. Vol. 113, N 1. P. 28 - 36.

50. Petti M.C. et al. High-dose hydroxyurea in the treatment of poor-risk myeloid leukemias // Ann. Hematol. 2003. Vol. 82, N 8. P. 476 - 480.

51. Kimby E., Nygren P., Glimelius B. A Systematic Overview of Chemotherapy Effects in Acute Myeloid Leukaemia // Acta Oncol. (Madr). 2001. Vol. 40, N 3. P. 231 - 252.

52. Wang J. et al. Meta-Analysis of Randomised Clinical Trials Comparing Idarubicin + Cytarabine with Daunorubicin + Cytarabine as the Induction Chemotherapy in Patients with Newly Diagnosed Acute Myeloid Leukaemia // PLoS One. 2013. Vol. 8, N 4. P. e60699.

53. Burnett A.K. et al. A randomized comparison of daunorubicin 90 mg/m2 vs 60 mg/m2in AML induction: Results from the UK NCRI AML17 trial in 1206 patients // Blood. 2015. Vol. 125, N 25. P. 3878 - 3885.

54. Hills RK, Castaigne S, Appelbaum FR et al: Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials. Lancet Oncol 15:986-996, 2014. DOI:10.1016/S1470-2045(14) 70281-5.

55. Lambert J, Pautas C, Terr C et al.: Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase 3 ALFA-0701 trial. Haematologica 104:113-119, 2019, DOI:10.3324/haematol.2018.188888

56. National Comprehensive Cancer Network (NCCN) Guidelines. 2-2022. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

57. Wu D. et al. Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: A network meta-analysis // Sci. Rep. 2017. Vol. 7, N 1. P. 9509.

58. Paciucci PA, Dutcher JP, Cuttner J, et al (1987) Mitoxantrone and ara-C in previously treated patients with acute myelogenous leukemia. Leukemia 1: 565 - 567.

59. Rodriguez-Morales A, Lopez JL, Sanchez P, et al (1991) Mitoxantrone (MTZ) and ARA-C high remission rate as first line therapy for acute myeloid leukemia (AML). Haematologica 76 [Suppl 4]: 127a.

60. Lambert J. et al. Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial. Haematologica. 2019 Jan;104(1):113-119.

61. Bashir Y. et al. Role of low dose cytarabine in elderly patients with acute myeloid leukemia: An experience // South Asian J. Cancer. Medknow, 2015. Vol. 4, N 1. P. 4.

62. Fong B., Van Bendegon J.M. Lumbar puncture. Neurologic and neurosurgical procedures // Rechman, E.F., Simon, R.R., eds. Emergency Medicine Procedures. New York: McGraw-Hill, 2004. P. 859 - 880.

63. Ye X.-N. et al. Epigenetic priming with decitabine followed by low-dose idarubicin/cytarabine has an increased anti-leukemic effect compared to traditional chemotherapy in high-risk myeloid neoplasms. // Leuk. Lymphoma. 2016. Vol. 57, N 6. P. 1311 - 1318.

64. Wei A.H. et al. Venetoclax Combined With Low-Dose Cytarabine for Previously Untreated Patients With Acute Myeloid Leukemia: Results From a Phase Ib/II Study. // J. Clin. Oncol. 2019. Vol. 37, N 15. P. 1277 - 1284.

65. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под ред. Е.Н. Паровичниковой. Том 1. - М.: Практика, 2024. - 928 с.

66. Кохно А.В. и соавт. Эффективность низкодозной терапии с гипометилирующим праймингом у больных МДС с избытком бластов (мдс-иб) и ОМЛ с изменениями, связанными с миелодисплазией (омл-мд) // Гематология и трансфузиология. 2020. NS1.

67. Pratz K. et al. Long-term follow-up of VIALE-A: Venetoclax and azacitidine in chemotherapy-ineligible untreated acute myeloid leukemia. Am J Hematol. 2024 Apr;99(4):615-624.

68. Dillon R. et al. Venetoclax combined with low dose cytarabine compared to standard of care intensive chemotherapy for the treatment of favourable risk adult acute myeloid leukaemia (VICTOR): Study protocol for an international, open-label, multicentre, molecularly-guided randomised, phase II trial. BMC Cancer 22, 1174 (2022).

69. DiNardo C.D. et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. // Blood. 2019. Vol. 133, N 1. P. 7 - 17.

70. Stone R.M. et al. Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation // N. Engl. J. Med. 2017. Vol. 377, N 5. P. 454 - 464.

71. DiNardo CD et al. 10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial. Lancet Haematol. 2020 Oct;7(10):e724-e736.

72. R llig C. et al. Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): A multicentre, phase 2, randomised controlled trial // Lancet Oncol. 2015. Vol. 16, N 16. P. 1691 - 1699.

73. Buchner T. et al. Long-term results in patients with acute myeloid leukemia (AML): The influence of high-dose AraC, G-CSF priming, autologous transplantation, prolonged maintenance, age, history, cytogenetics, and mutation status. Data of the AMLCG 1999 trial // Blood. 2009. Vol. 114, N 22. P. Abstract 485.

74. Соколов А.Н. et al. Долгосрочные результаты лечения острых миелоидных лейкозов у взрослых в многоцентровом клиническом исследовании ОМЛ 06.06 // Клиническая онкогематология. 2012. Vol. 5, N 1. P. 30 - 38.

75. Koreth J. et al. Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: Systematic review and meta-analysis of prospective clinical trials // JAMA - J. Am. Med. Assoc. 2009. Vol. 301, N 22. P. 2349 - 2361.

76. Godley L.A., Larson R.A. Therapy-Related Myeloid Leukemia // Semin. Oncol. 2008. Vol. 35, N 4. P. 418 - 429.

77. Fenaux P. et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study // Lancet Oncol. 2009. Vol. 10, N 3. P. 223 - 232.

78. Craddock C. et al. Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia // Haematologica. 2016. Vol. 101, N 7. P. 879 - 883.

79. Aldoss I. et al. Efficacy of the combination of venetoclax and hypomethylating agents in relapsed/refractory acute myeloid leukemia // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 9. P. e404 - e407.

80. Min CK, Kim DW, Lee JW, Min WS, Kim CC. Additional stem cell therapy for graft failure after allogeneic bone marrow transplantation. Acta Haematologica. 2000;104(4):185-92.

81. Rowe J.M. et al. A phase 3 study of three induction regimens and of priming with GM-CSF in older adults with acute myeloid leukemia: a trial by the Eastern Cooperative Oncology Group. // Blood. 2004. Vol. 103, N 2. P. 479 - 485.

82. Pophali P., Litzow M. What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction? // Current Treatment Options in Oncology. 2017. Vol. 18, N 1. P. 3.

83. Medeiros B.C. et al. Randomized study of continuous high-dose Lenalidomide, sequential Azacitidine and Lenalidomide, or azacitidine in persons 65 years and over with newly-diagnosed acute myeloid leukemia // Haematologica. Ferrata Storti Foundation, 2018. Vol. 103, N 1. P. 101 - 106.

84. He P.-F.F. et al. Efficacy and safety of decitabine in treatment of elderly patients with acute myeloid leukemia: A systematic review and meta-analysis // Oncotarget. Impact Journals LLC, 2017. Vol. 8, N 25. P. 41498 - 41507.

85. Burnett A.K. et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. // Cancer. 2007. Vol. 109, N 6. P. 1114 - 1124.

86. Cortes J.E. et al. Randomized comparison of low dose cytarabine with or without glasdegib in patients with newly diagnosed acute myeloid leukemia or high-risk myelodysplastic syndrome // Leukemia. Nature Publishing Group, 2019. Vol. 33, N 2. P. 379 - 389.

87. Bell J.A. et al. Effectiveness and Safety of Therapeutic Regimens for Elderly Patients With Acute Myeloid Leukemia: A Systematic Literature Review // Clin. Lymphoma, Myeloma Leuk. 2018. Vol. 18, N 7. P. e303 - e314.

88. Giles F. et al. Validation of the European Prognostic Index for younger adult patients with acute myeloid leukaemia in first relapse // Br. J. Haematol. Blackwell Publishing Ltd, 2006. Vol. 134, N 1. P. 58 - 60.

89. Thol F. et al. How I treat refractory and early relapsed acute myeloid leukemia // Blood. 2015. Vol. 126, N 3. P. 319 - 327.

90. Pastore D. et al. FLAG-IDA in the treatment of refractory/relapsed acute myeloid leukemia: Single-center experience // Ann. Hematol. 2003. Vol. 82, N 4. P. 231 - 235.

91. Hiddemann W. et al. High-dose cytosine arabinoside and mitoxantrone (Ham) for the treatment of refractory acute lymphoblastic leukemia // Oncol. Res. Treat. 1987. Vol. 10, N 1. P. 11 - 12.

92. Herzig R. et al. High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia. J Clin Oncol. 1985 Jul;3(7):992-7.

93. Marconi G. et al. MEC (mitoxantrone, etoposide, and cytarabine) induces complete remission and is an effective bridge to transplant in acute myeloid leukemia. Eur J Haematol. 2020 Jul;105(1):47-55.

94. Zhou X. et al. Epigenetic priming with decitabine followed by low dose idarubicin and cytarabine in acute myeloid leukemia evolving from myelodysplastic syndromes and higher-risk myelodysplastic syndromes: a prospective multicenter single-arm trial. Hematol Oncol. 2020 Oct;38(4):531-540.

95. Craddock C. et al. Factors predicting outcome after unrelated donor stem cell transplantation in primary refractory acute myeloid leukaemia // Leukemia. 2011. Vol. 25, N 5. P. 808 - 813.

96. Galtier J. et al. Intermediate-dose cytarabine or standard-dose cytarabine plus single-dose anthracycline as post-remission therapy in older patients with acute myeloid leukemia: impact on health care resource consumption and outcomes. Blood Cancer J. 2021 Nov 13;11(11):180.

97. Ye L. et al. Intermediate dose cytarabine improves survival and relapse-free rate compared with standard-dose cytarabine as post-remission treatment for acute myeloid leukemia: A retrospection study. Medicine (Baltimore). 2021 Jan 22;100(3):e24273.

98. National Comprehensive Cancer Network (NCCN) Guidelines: Acute Myeloid Leukemia. Version 3.2024 - May 17, 2024. [Electronic resource]. URL: https://www.nccn.org/professionals/physician_gls/pdf/aml.pdf

99. Fopp M. et al. Post-remission therapy of adult acute myeloid leukaemia: one cycle of high-dose versus standard-dose cytarabine. Leukaemia Project Group of the Swiss Group for Clinical Cancer Research (SAKK). // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 1997. Vol. 8, N 3. P. 251 - 257.

100. Hsu H.C. et al. Post-remission intensive consolidation with high-dose cytarabine-based chemotherapy and granulocyte colony-stimulatory factor in adults with acute myelogenous leukemia: a preliminary report. // Zhonghua Yi Xue Za Zhi (Taipei). 1995. Vol. 56, N 5. P. 305 - 311.

101. Frazer J. et al. Characteristics predicting outcomes of allogeneic Stem-Cell transplantation in relapsed acute myelogenous leukemia // Curr. Oncol. 2017. Vol. 24, N 2. P. e123 - e130.

102. Cruijsen M. et al. Clinical Results of Hypomethylating Agents in AML Treatment // J. Clin. Med. 2014. Vol. 4, N 1. P. 1 - 17.

103. Serve H. et al. Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: Results from a randomized, placebo-controlled trial // J. Clin. Oncol. American Society of Clinical Oncology, 2013. Vol. 31, N 25. P. 3110 - 3118.

104. Sasaki K, Kantarjian HM, Kadia T, et al. Sorafenib plus intensive chemotherapy improves survival in patients with newly diagnosed, FLT3-internal tandem duplication mutation-positive acute myeloid leukemia. Cancer. 2019;125(21):3755-3766.

105. Guenounou S, Delabesse E, C. Sorafenib plus all-trans retinoic acid for AML patients with FLT3-ITD and NPM1 mutations. Eur J Haematol. 2014;93(6):533-536.

106. Boissel N. et al. Dasatinib in high-risk core binding factor acute myeloid leukemia in first complete remission: A french acute myeloid leukemia intergroup trial // Haematologica. Ferrata Storti Foundation, 2015. Vol. 100, N 6. P. 780 - 785.

107. Трансплантация аллогенных гемопоэтических стволовых клеток. Практическое руководство. Под ред. Е.Н. Паровичниковой, Т.В. Гапоновой, М.Ю. Дрокова. - М.: Практика, 2024. с. 619 - 643 с.

108. Rautenberg C. et al. Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: Prevention, detection, and treatment // International Journal of Molecular Sciences. 2019. Vol. 20, N 1. P. 228.

109. Mamez A.C. et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. // Leuk. Lymphoma. 2016. Vol. 57, N 10. P. 2281 - 2288.

110. Bakst R.L. et al. How I treat extramedullary acute myeloid leukemia // Blood. 2011. Vol. 118, N 14. P. 3785 - 3793.

111. Chang A., Patel S. Treatment of Acute Myeloid Leukemia During Pregnancy // Annals of Pharmacotherapy. 2015. Vol. 49, N 1. P. 48 - 68.

112. Nakajima Y. et al. Acute leukemia during pregnancy: an investigative survey of the past 11 years // Int. J. Lab. Hematol. 2015. Vol. 37, N 2. P. 174 - 180.

113. Rolbin S.H. et al. Epidural anesthesia in pregnant patients with low platelet counts. // Obstet. Gynecol. 1988. Vol. 71, N 6 Pt 1. P. 918 - 920.

114. Salem M.N., Abbas A.M., Ashry M. Dexamethasone for the prevention of neonatal respiratory morbidity before elective cesarean section at term // Proc. Obstet. Gynecol. 2016. Vol. 6, N 3. P. 1 - 10.

115. J. et al. Chemotherapy-induced nausea and vomiting in acute leukemia and stem cell transplant patients: results of a multicenter, observational study. // Haematologica. 2006. Vol. 91, N 1. P. 84 - 91.

116. Kang K.-W. et al. Impact of G-CSF for Outcomes of Non-M3 AML Patients Who Were Treated By Anthracycline-Based Induction (7 + 3 regimen) Chemotherapies // Blood. 2015. Vol. 126, N 23. P. 4889 - 4889.

117. Delforge M. et al. Recommended indications for the administration of polyclonal immunoglobulin preparations // Acta Clin. Belg. 2011. Vol. 66, N 5. P. 346 - 360.

118. Anderson D. et al. Guidelines on the use of intravenous immune globulin for hematologic conditions. // Transfus. Med. Rev. 2007. Vol. 21, N 2 Suppl 1. P. S9 - 56.

119. Blumberg N. et al. Platelet transfusion and survival in adults with acute leukemia // Leukemia. Nature Publishing Group, 2008. Vol. 22, N 3. P. 631 - 635.

120. Delaflor-Weiss E., Mintz P.D. The evaluation and management of platelet refractoriness and alloimmunization // Transfus. Med. Rev. 2000. Vol. 14, N 2. P. 180 - 196.

121. DeZern A.E. et al. Red blood cell transfusion triggers in acute leukemia: a randomized pilot study // Transfusion. 2016. Vol. 56, N 7. P. 1750 - 1757.

122. Szczepiorkowski Z.M., Dunbar N.M. Transfusion guidelines: when to transfuse. // Hematology / the Education Program of the American Society of Hematology. American Society of Hematology. Education Program. 2013. Vol. 2013. P. 638 - 644.

123. Paul K.L. Rehabilitation and exercise considerations in hematologic malignancies. // Am. J. Phys. Med. Rehabil. 2011. Vol. 90, N 5 Suppl 1. P. S88 - 94.

124. Пантелеев М.А. et al. Практическая коагулология. 2010. 192 p.

125. Чернуха Г.Е. Аномальные маточные кровотечения репродуктивного периода // Гинекология: национальное руководство. Краткое издание. Под ред. Г.М. Савельевой. Г.Т. Сухих, В.Н. Серова, В.Е. Радзинского, И.Б. Манухина. М.: ГЭОТАР-Медиа, 2020. P. 170 - 175.

126. Доброхотова Ю.Э. et al. Аномальные маточные кровотечения: алгоритмы ведения, методы терапии // РМЖ. Мать и дитя. 2020. Vol. 3, N 1. P. 55 - 60.

127. Мамонов В.Е. Неотложная нейрохирургия внутричерепных кровоизлияний у пациентов гематологического стационара // Гематология и трансфузиология. 2020. Vol. 65, N S1. P. 174 - 175.

128. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство. Под ред. Е.Н. Паровичниковой и Г.М. Галстяна. - М.: Практика, 2024. - 512 с. стр. 145 - 173.

129. Annibali O. et al. Incidence of venous thromboembolism and use of anticoagulation in hematological malignancies: Critical review of the literature // Critical Reviews in Oncology/Hematology. Elsevier Ireland Ltd, 2018. Vol. 124. P. 41 - 50.

130. Falanga A., Marchetti M., Russo L. Venous thromboembolism in the hematologic malignancies // Current Opinion in Oncology. Curr Opin Oncol, 2012. Vol. 24, N 6. P. 702 - 710.

131. Воробьев А.И. et al. Гиперкоагуляционный синдром: классификация, патогенез, диагностика, терапия // Гематология и трансфузиология. 2016. Vol. 61, N 3. P. 116 - 122.

132. Greenberg C.S. The role of D-dimer testing in clinical hematology and oncology // Clin. Adv. Hematol. Oncol. 2017. Vol. 15, N 8. P. 580 - 583.

133. Weitz I.C. et al. Chemotherapy-induced activation of hemostasis: effect of a low molecular weight heparin (dalteparin sodium) on plasma markers of hemostatic activation // Thromb. Haemost. 2002. Vol. 88, N 2. P. 213 - 220.

134. Sharifi M. et al. New oral anticoagulants in the treatment of heparin - Induced thrombocytopenia // Thromb. Res. Elsevier Ltd, 2015. Vol. 135, N 4. P. 607 - 609.

135. Гендлин Г.Е. et al. Современный взгляд на кардиотоксичность химиотерапии онкологических заболеваний, включающей антрациклиновые антибиотики. // Российский кардиологический журнал. 2017. Vol. 143, N 3. P. 145 - 154.

136. Васюк Ю.А. et al. Возможности современных эхокардиографических технологий в ранней диагностике кардиотоксического действия химиотерапевтических препаратов антрациклинового ряда у онкологических больных. // Кардиология. 2017. Vol. 57, N S4. P. 31 - 17.

137. Zamorano J.L. et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines // European Heart Journal. Oxford University Press, 2016. Vol. 37, N 36. P. 2768 - 2801.

138. Larsen C.M., Mulvagh S.L. Cardio-oncology: What you need to know now for clinical practice and echocardiography // Echo Research and Practice. BioScientifica Ltd., 2017. Vol. 4, N 1. P. R33 - R41.

139. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство. Под ред. Е.Н. Паровичниковой и Г.М. Галстяна. - М.: Практика, 2024. - 512 с. стр. 247 - 262.

140. Narum S., Westergren T., Klemp M. Corticosteroids and risk of gastrointestinal bleeding: A systematic review and meta-analysis // BMJ Open. BMJ Publishing Group, 2014. Vol. 4, N 5.

141. Conn H.O., Poynard T. Corticosteroids and peptic ulcer: meta-analysis of adverse events during steroid therapy. // J. Intern. Med. J Intern Med, 1994. Vol. 236, N 6. P. 619 - 632.

142. Burget D.W., Chiverton S.G., Hunt R.H. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression // Gastroenterology. Gastroenterology, 1990. Vol. 99, N 2. P. 345 - 351.

143. Ивашкин В.Т. et al. Диагностика и лечение язвенной болезни у взрослых (Клинические рекомендации Российской гастроэнтерологической ассоциации, Российского общества колоректальных хирургов и Российского эндоскопического общества). // Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2020. Vol. 30, N 1. P. 49 - 70.

144. Scally B. et al. Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials // Lancet Gastroenterol. Hepatol. Elsevier Ltd, 2018. Vol. 3, N 4. P. 231 - 241.

145. Hu Z.-H. et al. Efficacy of proton pump inhibitors for patients with duodenal ulcers: A pairwise and network meta-analysis of randomized controlled trials // Saudi J. Gastroenterol. Medknow Publications, 2017. Vol. 23, N 1. P. 11.

146. Poynard T., Lemaire M., Agostini H. Meta-analysis of randomized clinical trials comparing lansoprazole with ranitidine or famotidine in the treatment of acute duodenal ulcer // Eur. J. Gastroenterol. Hepatol. 1995. Vol. 7, N 7. P. 661 - 665.

147. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство. Под ред. Е.Н. Паровичниковой и Г.М. Галстяна. - М.: Практика, 2024. - 512 с. стр. 293 - 310.

148. Охмат В.А. et al. Спектр и этиология инфекционных осложнений у больных острыми миелоидными лейкозами на этапах индукции и консолидации ремиссии // Гематология и трансфузиология. 2017. Vol. 62, N 1. P. 9 - 15.

149. Охмат В.А. et al. Инфекционные осложнения у взрослых больных острыми лимфобластными лейкозами на разных этапах химиотерапии по протоколу ОЛЛ-2009. // Онкогематология. 2017. Vol. 12, N 3. P. 31 - 40.

150. Клясова Г.А., Охмат В.А. Антимикробная терапия // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. Под редакцией Савченко В.Г. Москва: Практика, 2018. P. 1067 - 1114.

151. Maertens J. et al. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ECIL 32009 update // Bone Marrow Transplant. Nature Publishing Group, 2011. Vol. 46, N 5. P. 709 - 718.

152. Kollef M.H. et al. Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial // Lancet Infect. Dis. Lancet Publishing Group, 2019. Vol. 19, N 12. P. 1299 - 1311.

153. Debast S.B. et al. European society of clinical microbiology and infectious diseases: Update of the treatment guidance document for Clostridium difficile infection // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, N S2. P. 1 - 26.

154. Styczynski J. et al. Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: Guidelines from the Second European Conference on Infections in Leukemia // Bone Marrow Transplant. Bone Marrow Transplant, 2009. Vol. 43, N 10. P. 757 - 770.

155. Ljungman P. et al. Management of CMV, HHV-6, HHV-7 and Kaposi-sarcoma herpesvirus (HHV-8) infections in patients with hematological malignancies and after SCT // Bone Marrow Transplant. Bone Marrow Transplant, 2008. Vol. 42, N 4. P. 227 - 240.

156. Arendrup M.C. et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of rare invasive yeast infections // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, N S3. P. 76 - 98.

157. Tissot F. et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients // Haematologica. Ferrata Storti Foundation, 2017. Vol. 102, N 3. P. 433 - 444.

158. Мальчикова А.О., Клясова Г.А. Формирование биопленок у изолятов Candida spp, выделенных из гемокультуры от больных с опухолями системы крови // Клиническая микробиология и антимикробная химиотерапия. 2018. Vol. 20, N 2. P. 126 - 130.

159. Ullmann A.J. et al. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline // Clin. Microbiol. Infect. Elsevier B.V., 2018. Vol. 24. P. e1 - e38.

160. Cornely O.A. et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium // The Lancet Infectious Diseases. Lancet Publishing Group, 2019. Vol. 19, N 12. P. e405 - e421.

161. Tortorano A.M. et al. ESCMID and ECMM joint guidelines on diagnosis and management of hyalohyphomycosis: Fusarium spp., Scedosporium spp. and others // Clin. Microbiol. Infect. Blackwell Publishing Ltd, 2014. Vol. 20, N S3. P. 27 - 46.

162. Maschmeyer G. et al. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients // J. Antimicrob. Chemother. J Antimicrob Chemother, 2016. Vol. 71, N 9. P. 2405 - 2413.

163. Maertens J. et al. ECIL guidelines for preventing Pneumocystis jirovecii pneumonia in patients with haematological malignancies and stem cell transplant recipients // Journal of Antimicrobial Chemotherapy. Oxford University Press, 2016. Vol. 71, N 9. P. 1 - 8.

164. Абузарова Г.Р. Лечение болевого синдрома у онкологических больных // Российские клинические рекомендации по диагностике и лечению злокачественных лимфопролиферативных заболеваний; под ред. И.В. Поддубной, В.Г. Савченко. 2018. P. 278 - 288.

165. Когония Л.М. et al. Практические рекомендации по лечению хронического болевого синдрома у онкологических больных. // Злокачественные опухоли: Практические рекомендации RUSSCO. 2018. P. 617 - 635.

166. Fallon M. et al. Management of cancer pain in adult patients: ESMO Clinical Practice Guidelines. // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2018. Vol. 29, N Suppl 4. P. iv166 - iv191.

167. Авыдов О.С. et al. Невропатическая боль: клинические рекомендации по диагностике и лечению Российского общества по изучению боли // Российский журнал боли. 2018. Vol. 4. P. 5 - 40.

168. Baer M.R. et al. Cytarabine, Daunorubicin and Etoposide (ADE) Chemotherapy in Acute Myeloid Leukemia (AML) Patients 60 Years (CALGB 9720). // Blood. American Society of Hematology, 2007. Vol. 110, N 11. P. 296 - 296.

169. Сопроводительная терапия при лечении заболеваний системы крови. Практическое руководство. Под ред. Е.Н. Паровичниковой и Г.М. Галстяна. - М.: Практика, 2024. - 512 с. стр. 235 - 246.

170. Hann IM, Stevens RF, Goldstone AH, et al. Randomized comparison of DAT versus ADE as induction chemotherapy in children and younger adults with acute myeloid leukemia. Results of the Medical Research Council"s 10th AML trial (MRC AML10). Adult and Childhood Leukaemia Working Parties of the Medical Research Council. Blood. 1997;89(7):2311-2318.

171. Holowiecki, J. et al. (1997). Idarubicin, Cytarabine, Etoposide Versus Risk-Adjusted Daunorubicin Plus Cytosine Arabinoside for Induction Treatment of Acute Myeloid Leukemia: A Randomized Multicenter Trial. In: B chner, T., Schellong, G., Ritter, J., Creutzig, U., Hiddemann, W., , B. (eds) Acute Leukemias VI. Haematology and Blood Transfusion / und Bluttransfusion, vol 38. Springer, Berlin, Heidelberg.

172. Moore JO et al. Sequential multiagent chemotherapy is not superior to high-dose cytarabine alone as postremission intensification therapy for acute myeloid leukemia in adults under 60 years of age: Cancer and Leukemia Group B Study 9222. Blood. 2005 May 1;105(9):3420-7.

173. Fleischmann M, Jentzsch M, Brioli A, et al. Azacitidine in combination with shortened venetoclax treatment cycles in patients with acute myeloid leukemia. Ann Hematol. Published online October 25, 2024.

174. Kern W. et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia. 1998 Jul;12(7):1049-55.

175. Wei AH et al. Venetoclax plus LDAC for newly diagnosed AML ineligible for intensive chemotherapy: a phase 3 randomized placebo-controlled trial. Blood. 2020 Jun 11;135(24):2137-2145.

176. Perl AE et al. Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1 - 2 study. Lancet Oncol. 2017 Aug;18(8):1061-1075. Erratum in: Lancet Oncol. 2017 Dec;18(12):e711. Erratum in: Lancet Oncol. 2018 Jul;19(7):e335. Erratum in: Lancet Oncol. 2019 Jun;20(6):e293.

177. Perl A.E. et al. Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML // N Engl J Med. 2019. P. 1728 - 1740.

178. Short NJ et al. Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. J Clin Oncol. 2024 May 1;42(13):1499-1508.

179. Daver N. et al. Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. J Clin Oncol. 2022 Dec 10;40(35):4048-4059.

180. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под ред. Е.Н. Паровичниковой. Том 1. - М.: Практика, 2024. стр. 621 - 680.

181. Bazinet A. et al. Reduced dose azacitidine plus venetoclax as maintenance therapy in acute myeloid leukaemia following intensive or low-intensity induction: a single-centre, single-arm, phase 2 trial. Lancet Haematol. 2024 Apr;11(4):e287-e298.

182. Алгоритмы диагностики и протоколы лечения заболеваний системы крови: в двух томах. Под ред. Е.Н. Паровичниковой. Том 1. - М.: Практика, 2024. стр. 681 - 712.

183. Mark J. Levis et al., Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. JCO 42, 1766-1775(2024).

184. Chew S, Mackey MC, Jabbour E. Gilteritinib in the treatment of relapsed and refractory acute myeloid leukemia with a FLT3 mutation. Ther Adv Hematol. 2020 Jun 3;11:2040620720930614.

185. Троицкая В.В. et al. Протокол индукционной фазы лечения острых лейкозов, протекающих с гиперлейкоцитозом // Алгоритмы диагностики и протоколы лечения заболеваний системы крови. НМИЦ Гематологии. Под ред. В.Г. Савченко. Практика, 2018. P. 731 - 752.

186. Giammarco S. et al. Hyperleukocytosis and leukostasis: management of a medical emergency // Expert Review of Hematology. Taylor and Francis Ltd, 2017. Vol. 10, N 2. P. 147 - 154.

187. R llig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246-3252.

188. Mamez A.C. et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia // Leuk. Lymphoma. Taylor and Francis Ltd, 2016. Vol. 57, N 10. P. 2281 - 2288.

189. Ganzel C. et al. Hyperleukocytosis, leukostasis and leukapheresis: Practice management // Blood Rev. Blood Rev, 2012. Vol. 26, N 3. P. 117 - 122.

190. SPIRIN M., GALSTYAN G., DROKOV M. Central venous access in lymphoma patients (pts) with superior vena cava syndrome (SVCS) // INTENSIVE CARE Med. Exp. 2019. Vol. 7, N Suppl. 3:001341. P. 388 - 389.